

Stefania Volpe MD, PhD

E-mail Address: stefania.volpe@ieo.it; dr.stefaniavolpe@gmail.com

Date of Birth: 26/09/1988

Nationality: Italian

C.F. VLPSFN88P66F205M

PROFESSIONAL EXPERIENCE

12/2023- Present

Research Associate- Ricercatore a tempo determinato di tipo A (RTDA)

University of Milan, Dept. of Oncology and Hemato-oncology, Via Festa del Perdono 7, 20122, Milan, Italy

12/2019- Present

Radiation Oncologist

European Institute of Oncology (IEO) IRCCS, Via Ripamonti 435, 20141, Milan, Italy

EDUCATION TRAINING

AND

09/2019- 12/2023

PhD Program- System Medicine/ Computational Biology Curriculum

European Institute of Oncology (IEO) IRCCS, Via Ripamonti 435, 20141, Milan, Italy

Research training and activity on precision radiotherapy, with the development of specific knowledge in the areas of Biology, Medicine, Mathematics, Statistics and Information Technology.

05/2022- 05/2022

Clinical Observership- Radiation Oncologist

University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen 9713, Groningen, Netherlands

Clinical activities, with a specific focus on proton therapy applications (indication, treatment planning, normal tissue complication probability- NTCP modeling)

12/2014- 12/2019

Resident- Radiation Oncology

Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Via Festa del Perdono 7, 20122 Milan, Italy

European Institute of Oncology (IEO) IRCCS, Via Ripamonti 435, 20141, Milan, Italy

Provide general clinical care in outpatient clinics, manage radiation- related toxicities, assistance in treatment planning, clinical research activity.

01/04/2014- 30/09/2019

Clinical and Research Observership

Centre Antoine Lacassagne- Institut Méditerranéen de ProtonThérapie, 227 Av. de la Lanterne, 06200 Nice, France

Clinical activities, with a specific focus on proton therapy applications and pediatric cancers

01/04/2017- 30/09/2017

Rotating Resident- Research

MD Anderson Cancer Center - Department of Radiation Oncology, Houston (TX), United States of America

Clinical research activities, research focus is personalized radiotherapy techniques by incorporation of novel imaging methodologies (e.g. Radiomics) and predictive modeling in the setting of Head and Neck tumors.

01/07/2014- 31/03/2016

Medical Doctor on Call

Azienda Sanitaria Locale di Milano, Milan, Italy

General medicine practice and care during week- ends and night shifts, provide patient diagnosis under strict time constraints

20/07/2013- 31/07/2014

Medical Assistant

Azienda Ospedaliera San Paolo- Medical Oncology Department, Milan, Italy

Assistance in daily clinical practice in inpatient and outpatient clinics, palliative care, management of chemotherapy- related toxicities

03/2011- 07/2013

Medical Undergraduate Training

Medical Oncology Department- Azienda Ospedaliera San Paolo, Via Antonio di Rudinì 8, 20142, Milan, Italy

Assistance in daily clinical practice in inpatient and outpatient clinics, palliative care

09/2007- 07/2013

Medical Degree with Honors

Università degli Studi di Milano- Via Festa del Perdono 7, 20122, Milan, Italy

Dissertation Titled: "Prognostic value of KRAS and BRAF mutation status in patients treated by liver metastasectomy for colo- rectal cancer"

09/2002- 07/2007

High School Diploma with Honors

Liceo Scientifico Statale Luigi Cremona, Viale Marche 71/73, 20159, Milan, Italy

LANGUAGE SKILLS

Native Language

Italian

Foreign Languages

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C1
French	C1	C1	B2	B2	B2
Arabic	A1	A1	A1	A1	A1

TECHNICAL SKILLS AND QUALIFICATIONS

02.2023 Abilitazione Scientifica Nazionale alle funzioni di Professore di II fascia- Ministero dell'Università e della Ricerca (MIUR)- National Scientific Qualification.

Use of RayStation, Velocity AI, MIM Vista, iPlanet, Eclipse treatment planning systems

Use of Python programming language (intermediate level, DataCamp certificate)

Use of Image Biomarker Explorer (IBEX) for Radiomics Analysis

Use of medical and scientific databases

Tutoring and teaching activities for Residents in the Radiation Oncology School (University of Milan), Medicine and Surgery, Biomedical Omics and TSRM (University of Milan) and students of the Department of Electronics, Information and Bioengineering (Politecnico of Milan)

Reviewer experience for peer-reviewed indexed medical journals

PERSONAL SKILLS

Good team player as well as independent worker

Fast, highly motivated learner

Strong problem solving and analytical skills

Ability to establish and maintain a positive working environment and personal relationship with patients and colleagues

AWARDED GRANTS

Associazione Italiana per la Ricerca sul Cancer (AIRC): “MONDRIAN: multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer”, 2023-ongoing (Principal Investigator)

SCIENTIFIC ACTIVITIES- OTHER

2024- Present: Member of the working group of the Italian Association of Radiobiology- AIRB (Associazione Italiana di Radiobiologia)

2022: Panelist for the Regional PDTA (Percorsi Diagnostici Terapeutici ed Assistenziali) on behalf of the Italian Association for Head and Neck Oncology- AIOCC (Associazione Italiana Oncologia Cervico-Cefalica)

2021- 2022: Member of the Head and Neck Cancer working group of the Italian Association of Radiation Oncology and Clinical Oncology- AIRO (Associazione Italiana di Radioterapia Oncologica e Oncologia Clinica)

2020: Panelist for the Regional PDTA (Percorsi Diagnostici Terapeutici ed Assistenziali) on behalf of the Italian Association for Head and Neck Oncology- AIOCC (Associazione Italiana Oncologia Cervico-Cefalica)

2019: Member of the panel for Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)- based guidelines preparation, on behalf of the Italian Association of Radiation Oncology and Clinical Oncology- AIRO (Associazione Italiana di Radioterapia Oncologica e Oncologia Clinica)

2018- Present: Member of the Institutional Radiomics Working Group at the European Institute of Oncology, IEO (Istituto Europeo di Oncologia, Milan, Italy)

PUBLICATIONS:

Total number of full-text, peer-reviewed publications: 81

H-Index: 20, Number of Citations: 1677

1. **CT-Based Radiomics Enhance Respiratory Function Analysis for Lung SBRT**
Porazzi A, Raimondi S, Piperno G, Franzetti J, Mastroleo F, Volpe S, et al.
Bioengineering. 2025;12(8):800. doi: 10.3390/bioengineering12080800.
2. **Perineural invasion and parotid involvement in auricular cutaneous SCC: Which volumes to treat in postoperative radiotherapy?**
Critelli P, Parisi S, Alterio D, ... Volpe S, ... Merlotti A.
Tumori. 2025 Jun;111(3):210-218. doi: 10.1177/03008916251334879.
3. **Harnessing Baseline Radiomic Features in Early-Stage NSCLC: What Role in Clinical Outcome Modeling for SBRT Candidates?**
Volpe S, Vincini MG, Zaffaroni M, Gaeta A, Raimondi S, Piperno G, et al.
Cancers (Basel). 2025 Mar 6;17(5):908. doi: 10.3390/cancers17050908.
4. **Facing the climate change: is radiotherapy as green as we would like? A systematic review**
Volpe S, Mastroleo F, Vincini MG, Zaffaroni M, Marvaso G, Jereczek-Fossa BA.
Crit Rev Oncol Hematol. 2024 Dec; 204:104500. doi: 10.1016/j.critrevonc.2024.104500.
5. **The prognostic role of MRI-based radiomics in tongue carcinoma: a multicentric validation study.**
Tagliabue M, Ruju F, Mossinelli C, Gaeta A, Raimondi S, **Volpe S**, Zaffaroni M, Isaksson LJ, Garibaldi C, Cremonesi M, Rapino A, Chiocca S, Pietrobon G, Alterio D, Trisolini G, Morbini P, Rampinelli V, Grammatica A, Petralia G, Jereczek-Fossa BA, Preda L, Ravanelli M, Maroldi R, Piazza C, Benazzo M, Ansarin M.
Radiol Med. 2024 Aug 3. doi: 10.1007/s11547-024-01859-y. Epub ahead of print.
6. **Dosimetric and NTCP analyses for selecting parotid gland cancer patients for proton therapy.**
Camarda AM, Vincini MG, Russo S, Comi S, Emiro F, Bazani A, Ingargiola R, Vischioni B, Vecchi C, **Volpe S**, Orecchia R, Jereczek-Fossa BA, Orlandi E, Alterio D.
Tumori. 2024 Aug;110(4):273-283. doi: 10.1177/03008916241252544. Epub 2024 May 21
7. **Post-operative intensity-modulated vs 3D conformal radiotherapy after conservative surgery for laryngeal tumours of the supraglottic region: a dosimetric analysis on 20 patients.**
Alterio D, Marani S, Vigorito S, Zurlo V, Zorzi SF, Ferrari A, **Volpe S**, Bandi F, Vincini MG, Gandini S, Gaeta A, Fodor CI, Casbarra A, Zaffaroni M, Starzynska A, Belgioia L, Ansarin M, Aristei C, Jereczek-Fossa BA.
Acta Otorhinolaryngol Ital. 2024 Jun;44(3):150-160. doi:10.14639/0392-100X-N2442.
8. **Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis**
Corrao G, Marvaso G, Mastroleo F, Biffi A, Pellegrini G, Minari S, Vincini MG, Zaffaroni M, Zerini D, **Volpe S**, Gaito S, Mazzola GC, Bergamaschi L, Cattani F, Petralia G, Musi G, Ceci F, De Cobelli O, Orecchia R, Alterio D, Jereczek-Fossa BA.
Radiother Oncol. 2024 Jun;195:110264. doi:10.1016/j.radonc.2024.110264. Epub 2024 Mar 30.
9. **A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.**
Alterio D, Vincini MG, **Volpe S**, Bergamaschi L, Zaffaroni M, Gandini S, Peruzzotti G, Cattani F, Garibaldi C, Jereczek-Fossa BA, Orecchia R.
BMC Cancer. 2024 Mar 12;24(1):333. doi: 10.1186/s12885-024-12059-2
10. **3D-printed boluses for radiotherapy: influence of geometrical and printing parameters on dosimetric characterization and air gap evaluation**
Gugliandolo SG, Pillai SP, Rajendran S, Vincini MG, Pepa M, Pansini F, Zaffaroni M, Marvaso G, Alterio D, Vavassori A, Durante S, **Volpe S**, Cattani F, Jereczek-Fossa BA, Moscatelli D, Colosimo BM
Radiol Phys Technol. 2024 Jun;17(2):347-359. doi: 10.1007/s12194-024-00782-1.
11. **Post-operative KEloids iRadiation (POKER): does the surgery/high-dose interventional radiotherapy association make a winning hand?**
Franzetti J, Durante S, Mastroleo F, **Volpe S**, De Lorenzi F, Rotondi M, Lorubbio C, Vitullo A, Frassoni S, Bagnardi V, Cambria R, Cattani F, Vavassori A, Jereczek-Fossa BA.
Radiol Med. 2024 Feb;129(2):328-334. doi: 10.1007/s11547-024-01756-4. Epub 2024

12. **Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study**
Volpe S, Volpe S, Zaffaroni M, Piperno G, Vincini MG, Zerella MA, Mastroleo F, Cattani F, Fodor CI, Bellerba F, Bonaldi T, Bonizzi G, Ceci F, Cremonesi M, Fusco N, Gandini S, Garibaldi C, Torre D, Noberini R, Petralia G, Spaggiari L, Venetis K, Orecchia R, Casiraghi M, Jereczek-Fossa BA.
 BMC Cancer. 2023 Dec 15;23(1):1236. doi: 10.1186/s12885-023-11701-9.
13. **Hippocampal region avoidance in whole brain radiotherapy in brain metastases: For all or for some? A real-world feasibility report**
 Corrao G, Bergamaschi L, Pierini VE, Gaeta A, **Volpe S**, Pepa M, Zaffaroni M, Vincini MG, Fodor CI, Piperno G, Emiro F, Ferrari A, Gandini S, Cattani F, Marvaso G, Jereczek-Fossa BA
 Tumori Journal 2023, Accepted Manuscript, <https://doi.org/10.1177/03008916231206926>
14. **More than Five Decades of Proton Therapy: A Bibliometric Overview of the Scientific Literature**
 Vincini MG, Zaffaroni M, Schwarz M, Marvaso G, Mastroleo F, **Volpe S**, Bergamaschi L, Mazzola GC, Corrao G, Orecchia R, Jereczek Fossa BA and Alterio D
 Cancers 2023, 15(23), 10.3390/cancers15235545
15. **Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients**
 Rinaldi L, Guerini Rocco E, Spitaleri G, Raimondi S, Attili I, Ranghiero A, Cammarata G, Minotti M, o Presti G, De Piano F, Bellerba F, Funicelli G, **Volpe S**, Mora S, Fodor C, Rampinelli C, Barberis M, De Marinis F, Jereczek-Fossa BA, Orecchia R
 Cancers 2023, 15(18), 4553; <https://doi.org/10.3390/cancers15184553>.
16. **Hypofractionated proton therapy for benign tumors of the Central Nervous System: a systematic review of the literature**
 Piperno G, Ferrari A, **Volpe S***, Cattani F, Zaffaroni M, Comi S, Pansini F, Bergamaschi L, Mazzola GC, Ceci F, Colandrea M, Petralia G, Orecchia R, Alterio D, Jereczek-Fossa BA
 Crit Rev Oncol Hematol 2023 Sep 6;191:104114. doi: 10.1016/j.critrevonc.2023.104114.
17. **Patients' needs in Proton Therapy: a survey among ten European Facilities**
 Mazzola GC, Bergamaschi L, Pedone C, Vincini MG, Pepa M, Zaffaroni M, **Volpe S**, Rombi B, Doyen J, Fossati P, Haustermans K, Høyer M, Lagendijk JA, Matute R, Orlandi E, Rylander H, Troost E, Orecchia R, Alterio D, Jereczek-Fossa BA
 Clin Transl Radiat Oncol, 2023. November 2023, 100670, vol 43, doi: 10.1016/j.ctro.2023.100670
18. **Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach, part I: prognostic factors and indication to treatment**
 Alterio D, Zaffaroni M, Bossi P, Dionisi F, Elicin O, Falzone A, Ferrari A, Jereczek-Fossa BA, Sanguineti G, Szturz P, **Volpe S**, Scricciolo M.
 Radiol Med, <https://doi.org/10.1007/s11547-023-01713-7>
19. **Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach, part II: radiation technique and fractionations**
 Alterio D, Zaffaroni M, Bossi P, Dionisi F, Elicin O, Falzone A, Ferrari A, Jereczek-Fossa BA, Sanguineti G, Szturz P, **Volpe S**, Scricciolo M.
 Radiol Med, 2023 Aug;128(8):1007-1021. doi: 10.1007/s11547-023-01671-0.
20. **Blood- and Imaging-Derived Biomarkers for Oncological Outcome Modelling in Oropharyngeal Cancer: Exploring the Low-Hanging Fruit**
Volpe S, Gaeta A, Colombo F, Zaffaroni M, Mastroleo F, Vincini MG, Pepa M, Isaksson LJ, Turturici I, Marvaso G, Ferrari A, Cammarata G, Santamaria R, Franzetti J, Raimondi S, Botta F, Ansarin M, Gandini S, Cremonesi M, Orecchia R, Alterio D, Jereczek-Fossa BA
 Cancers, 2023 Mar 28;15(7):2022. doi: 10.3390/cancers15072022.
21. **Quo Vadis Radiomics? Bibliometric analysis of 10-year Radiomics journey**
Volpe S, Mastroleo F, Krengli M, Jereczek-Fossa BA
 European Radiology 2023 Apr 18;1-10. doi: 10.1007/s00330-023-09645-6. Online ahead of print.
22. **Can Ki-67 predict radiotherapy response in neuroendocrine tumors? Retrospective analysis of a monocentric series of patient**

Zerini D, Rotondi M, **Volpe S**, Pisa E, Frigo E, Pedone C, Flospergher M, Bagnardi V, Frassoni S, Fodor CI, Spada F, Fazio N, Alterio D, Jereczek-Fossa BA

Tumori Journal 2023, Accepted, Ahead of print

23. The role of radiomics in tongue cancer: a new tool for prognosis prediction

Mossinelli C, Tagliabue M, Ruju F, Cammarata G, **Volpe S***, Raimondi S, Zaffaroni M, Isaksson LJ, Garibaldi C, Cremonesi M, Corso F, Gaeta A, Emili I, Zorzi S, Alterio D, Marvaso G, Pepa M, De Fiori E, Maffini F, Preda L, Benazzo M, Jereczek-Fossa BA, Ansarin M

Head and Neck 2023, 45(4), 849-861; doi: 10.1002/hed.27299

24. Comparison of automated segmentation techniques for magnetic resonance images of the prostate

Isaksson LJ, Pepa M, Summers P, Zaffaroni M, Vincini MG, Corrao G, Mazzola GC, Rotondi M, Lo Presti G, Raimondi S, Gandini S, **Volpe S**, Haron Z, Alessi S, Pricolo P, Mistretta FA, Luzzago S, Cattani F, Musi G, De Cobelli O, Cremonesi M, Orecchia R, Marvaso G, Petralia G, Jereczek-Fossa BA

BMC Med Imaging 2023, 23(1):32, doi: 10.1186/s12880-023-00974-y.

25. Prognostic Impact of Sarcopenia's Occurrence During Radiotherapy in Oropharyngeal Cancer Patients

Ferrante M, Bergamaschi L, Marvaso G, Zaffaroni M, Vincini MG, D'Ecclesiis O, **Volpe S**, Ferrari A, Zorzi SF, Cossu Rocca M, Sabbatini A, Cannillo G, Zagallo E, Starzynska A, Ansarin M, Cattani F, Gandini S, Orecchia R, Alterio D, Jereczek-Fossa BA

Cancers 2023, 15(3), 723; <https://doi.org/10.3390/cancers15030723>

26. Application of the nnU-Net for automatic segmentation of lung lesions on CT images, and implication on radiomic models

Ferrante M, Rinaldi L, Botta F, Hu X, Dolp A, Minotti M, De Piano F, Funicelli G, **Volpe S**, Bellerba F, De Marco P, Raimondi S, Rizzo S, Shi K, Cremonesi M, Jereczek-Fossa BA, Spaggiari L, de Marinis F, Orecchia R, Origgi D

J Clin Med. 2022 Dec 9;11(24):7334. doi: 10.3390/jcm11247334.

27. Brain metastases from NSCLC treated with stereotactic radiotherapy: prediction mismatch between two different radiomic platforms

Carlioni G, Garibaldi C, Marvaso G, **Volpe S**, Zaffaroni M, Pepa M, Isaksson LJ, Colombo F, Durante S, Lo Presti G, Raimondi S, Spaggiari L, de Marinis F, Piperno G, Vigorito S, Gandini S, Cremonesi M, Positano V, Jereczek-Fossa BA

Radiother Oncol 2022 Nov 24; 178:109424, doi: 10.1016/j.radonc.2022.11.013.

28. Virtual and Augmented Reality as a Novel Opportunity to Unleash the Power of Radiotherapy in the Digital Era: A Scoping Review

Marvaso G, Pepa M, **Volpe S**, Mastroleo F, Zaffaroni M, Vincini MG, Corrao G, Bergamaschi L, Mazzocco K, Pravettoni G, Orecchia R, Jereczek-Fossa BA

Appl. Sci. 2022, 12(22), 11308; <https://doi.org/10.3390/app122211308>

29. Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis

Volpe S, Piperno G, Colombo F, Biffi A, Comi S, Mastroleo F, Camarda AM, Casbarra A, Cattani F, Corrao G, De Marinis F, Spaggiari L, Guckenberger M, Orecchia R, Alterio D, Jereczek-Fossa BA

Cancer Treat Rev 2022 Nov; 110:102464. doi: 10.1016/j.ctrv.2022.102464.

30. Impact of image filtering and assessment of volume-confounding effects on CT radiomic features and derived survival models in NSCLC

Volpe S, Isaksson LJ, Zaffaroni M, Pepa M, Raimondi S, Botta F, Lo Presti G, Vincini MG, Rampinelli C, Cremonesi M, Cremonesi M, de Marinis F, Spaggiari L, Gandini S, Guckenberger M, Orecchia R, Jereczek-Fossa BA

Journal of Translational Lung Cancer Research. doi: 10.21037/tlcr-22-248

31. Upfront transoral robotic surgery (TORS) versus intensity-modulated radiation therapy (IMRT) in HPV-positive oropharyngeal cancer: real-world data from a tertiary comprehensive cancer center

Zorzi S, Agostini G, Chu F, Tagliabue M, Pietrobon G, Corrao G, **Volpe S**, Marvaso G, Colombo F, Cossu Rocca M, Gandini S, Gaeta A, Ruju F, Alterio D, Ansarin M

Acta Oncol Italica. 2022 10.14639/0392-100X-N2144

32. Intensity-Modulated Radiotherapy (IMRT) following Conservative Surgery of the Supraglottic Region: Impact on Functional Outcomes

Alterio D, Marani S, Zurlo V, Zorzi SF, Ferrari AM, **Volpe S**, Bandi F, Vigorito S, Vincini MG, Gandini S, Gaeta A, Fodor CI, Casbarra A, Zaffaroni M, Stazynska A, Belgioia L, Ansarin M, Aristei C, Jereczek-Fossa BA

Cancers. 2022, 14(11), 2600; <https://doi.org/10.3390/cancers14112600>

- 33. Stereotactic Radiotherapy Ablation and Atrial Fibrillation: technical issues and clinical expectations derived from a systematic review**
Franzetti J, **Volpe S***, Catto V, Conte E, Piccolo C, Pepa M, Piperno G, Camarda AM, Cattani F, Andreini D, Tondo C, Jereczek-Fossa BA, Carbucicchio C
Front Cardiovasc Med and Card Rhythm. 2022. doi: 10.3389/fcvm.2022.849201
- 34. Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature**
Alterio D, La Rocca E, **Volpe S***, Camarda AM, Casbarra A, Russel-Edu W, Zerella MA, Orecchia R, Galimberti V, Veronesi P, Leonardi MC, Jereczek-Fossa BA
Breast Cancer Res Treat. 2022 Jan 13. doi: 10.1007/s10549-022-06516-4.
- 35. Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer**
Volpe S, Marvaso G, Pepa M, Zaffaroni M, Corrao G, Augugliaro M, Nolè F, De Cobelli O, Jereczek-Fossa BA
Cancer Manag Res. 2022 Jan 6;14:89-101. doi: 10.2147/CMAR.S321136
- 36. Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis**
Corrao G, Marvaso M, Zaffaroni M, **Volpe S**, Augugliaro M, Fodor CI, Zerini D, Vingiani A, Mistretta FA, Luzzago S, Alessi S, Pricolo P, Musi G, De Cobelli O, Renne G, Manzoni M, Petralia G, Orecchia R, Jereczek-Fossa BA
Neoplasma . 2022 Jan 12;210622N828. doi: 10.4149/neo_2021_210622N828.
- 37. Indication to postoperative radiotherapy for oral cavity squamous cell carcinoma: what's new in the Depth of Infiltration (DOI) era?**
Alterio D, De Berardinis R, Augugliaro M, D'Urso P, **Volpe S**, Maffini F, Bruschini R, Marvaso G, Riccio S, Tagliabue M, Turturici I, Farneti A, Calabrese L, Starzynska A, Ferrari A, Zaffaroni M, Jereczek-Fossa BA, Sanguineti G, Ansarin M
Br J Radiol. 2021 Dec 17;20210705. doi: 10.1259/bjr.20210705.
- 38. Machine Learning for Head and Neck Cancer: A Safe Bet? —A Clinically Oriented Systematic Review for the Radiation Oncologist**
Volpe S, Pepa M, Zaffaroni M, Bellerba F, Santamaria R, Marvaso G, Isaksson LJ, Gandini S, Starzyńska A, Leonardi MC, Orecchia R, Alterio D, Jereczek-Fossa BA
Front. Oncol., 18 November 2021 | <https://doi.org/10.3389/fonc.2021.772663>
- 39. Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300**
Marvaso G, Vischioni B, Pepa M, Zaffaroni M, **Volpe S***, Patti F, Bellerba F, Gandini S, Comi S, Corrao G, Zerini D, Augugliaro M, Fodor C, Russo S, Molinelli S, Ciocca M, Ricotti R, Valvo F, Giandini T, Avuzzi B, Valdagni R, De Cobelli O, Cattani F, Orlandi E, Jereczek-Fossa BA, Orecchia R.
Front. Oncol., 17 November 2021 | <https://doi.org/10.3389/fonc.2021.778729>
- 40. The Impact of Post-Operative Radiotherapy in Early Stage (pT1-pT2N0M0) Oral Tongue Squamous Cell Carcinoma in Era of DOI**
Alterio D, D'Urso P, **Volpe S***, Tagliabue M, Berardinis R, Augugliaro M, Gandini S, Maffini FA, Bruschini R, Turturici I, Riccio S, Calabrese L, Farneti A, Starzyńska A, Ferrari AM, Jereczek-Fossa BA, Ansarin M, Sanguineti G
Cancers (Basel). 2021 Sep 28;13(19):4851. doi: 10.3390/cancers13194851. PMID: 34638335
- 41. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy**
Leonardi MCL, Arrobio C, Gandini S, **Volpe S***, Colombo F, La Rocca E, Galimberti V, Kahler-Ribeiro-Fontana K, Fodor C, Dicuonzo S, Rojas DP, Zerella MA Morra A, Montagna E, Colleoni M, Mazzaro G, Travaini LL, Zaffaroni M, Jereczek-Fossa BA
Radiother Oncol. 2021 Aug 27; S0167-8140(21)06707-4. doi: 10.1016/j.radonc.2021.08.013.
- 42. Biomedical Omics: first insights of a new Master of Science Degree of the University of Milan (Italy)**
Alcalay M, Jereczek-Fossa BA, Pepa M, **Volpe S***, Zaffaroni M, Fiore F, Marvaso G, Pravettoni G, Curigliano G, Santaguida S, Pelicci PG
Tumori. 2021 Sep 29;3008916211047268. doi: 10.1177/03008916211047268.
- 43. Postsurgical geometrical variations of tumor bed and brainstem during photon and proton therapy for pediatric tumors of the posterior fossa: dosimetric impact and predictive factors**
Volpe S*, Bondiau PY, Claude L, Claren A, Padovani L, AlGhamdi H, Duhil De Benaze G, Opitz L, Baudin G, Dejean C, Maneval D, Jereczek-Fossa BA, Doyen J
Strahlentherapie und Onkologie, August 2021, <https://doi.org/10.1007/s00066-021-01828-8>
- 44. Therapeutic sequences in the treatment of high-risk prostate cancer: paving the way towards multimodal tailored approaches**

Marvaso G, Corrao G, Zaffaroni M, Pepa M, Augugliaro M, **Volpe S**, Musi G, Luzzago S, Mistretta FA, Verri E, Cossu Rocca M, Ferro M, Petralia G, Nolè F, De Cobelli O, Orecchia R, Jereczek-Fossa BA
Front Oncol. 2021 Aug 4;11:732766. doi: 10.3389/fonc.2021.732766. eCollection 2021.

45. miRNA signature for oligorecurrent prostate cancer characterization: the biological challenge behind clinical practice. Benchmark for the RADIOSA trial: a narrative review

Corrao G, Zaffaroni M, Bergamaschi L, Augugliaro M, **Volpe S**, Pepa M, Bonizzi G, Pece S, Amodio N, Mistretta FA, Luzzago S, Musi G, Alessi S, La Fauci FM, Tordonato C, Cattani F, Gandini S, Petralia G, Pravettoni G, De Cobelli O, Viale G, Orecchia O, Marvaso G, Jereczek-Fossa BA
Cancers, 2021; Accepted

46. 18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer

Elhalawani H, Cardenas CE, **Volpe S**, Barua S, Stieb S, Rock CB, Lin T, Yang P, Wu H, Zaveri J, Elgohari B, Abdallah LE, Jethanandani A, Mohamed ASR, Court LE, Hutcheson KA, Gunn GB, Rosenthal DI, Frank SJ, Garden AS, Rao A, Fuller CD
Clin Transl Radiat Oncol. 2021 Jun 6;29:93-101. doi: 10.1016/j.ctro.2021.05.011. eCollection 2021 Jul.

47. Computed Tomography Radiomics Kinetics as Early Imaging Correlates of Osteoradionecrosis in Oropharyngeal Cancer Patients

Barua S, Elhalawani H, **Volpe S**, Al Feghali KA, Yang P, Ng SP, Elgohari B, Granberry RC, Mackin DS, Gunn GB, Hutchenson K, Chambers MS, Court LE, Mohamed ASR, Fuller CD, Lai SY, Rao A.
Front. Artif. Intell., 09 April 2021 | <https://doi.org/10.3389/frai.2021.618469>

48. The T-N tract involvement as a new prognostic factor for PORT in locally advanced oral cavity tumors

Alterio D, Augugliaro M, Tagliabue M, Bruschini R, Gandini S, Calabrese L, Belloni P, Preda L, Maffini FA, Marvaso G, Ferrari A, **Volpe S***, Zerella MA, Oneta O, Turturici I, Alessandro O, Ruju F, Ansarin M, Orecchia R, Jereczek-Fossa BA
Oral Dis. 2021 Apr 24. doi: 10.1111/odi.13885.

49. Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies

Marvaso G, **Volpe S***, Pepa M, Augugliaro M, Corrao G, Biffi, A, Zaffaroni, M, Bergamaschi L, La Fauci FM, Mistretta FA, Luzzago S, Cattani F, Musi G, Petralia G, Pravettoni G, De Cobelli O, Orecchia R, Jereczek-Fossa B.A.
European Urology Open Science, Volume 27, May 2021, Pages 19-28 <http://dx.doi.org/10.1016/j.euros.2021.02.008> 2666-1683/© 2021

50. Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Reverberi C, **Volpe S***, Balestrini D, Buglione M, Navarria P, Scoccianti S, Panciani P, Krengli M, Pirtoli L, Bordi L, Pappagallo GL, D'Angelillo RM, Magrini SM, Arcangeli S.
Journal of Cancer Research and Clinical Oncology; doi:10.1007/s00432-021-03515-8

51. Association of quantitative MRI-based radiomic features with prognostic factors and recurrence rate in oropharyngeal squamous cell carcinoma

C Giannitto, G Marvaso, F Botta, S Raimondi, D Alterio, D Ciardo, **S Volpe**, F De Piano, E Ancona, M Tagliabue, D Origgi, S Chiocca, F Antonio Maffini, M Ansarin, V Bagnardi, F Cattani, F Nolè, L Preda, R Orecchia, E Cassano, M Cremonesi, A Starzyńska, M Bellomi, B Alicja Jereczek-Fossa
Neoplasma. 2020 Nov;67(6):1437-1446. doi: 10.4149/neo_2020_200310N249. Epub 2020 Aug 13. DOI: 10.4149/neo_2020_200310N249

52. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage

M. Kamal, A.S.R. Mohamed, C.D. Fuller, E.M. Sturgis, F.M. Johnson, W.H. Morrison, G.B. Gunn, K.A. Hutcheson, J. Phan, S. **Volpe, S**. Ping Ng, J. Phan, C. Cardenas, R. Ferrarotto, S.J. Frank, David I. Rosenthal, Adam S. Garden
Adv Radiat Oncol. 2020 Sep-Oct; 5(5): 929–935. doi: 10.1016/j.adro.2020.04.025PMCID: PMC7557124

53. Carotid blowout syndrome after reirradiation for head and neck malignancies: a comprehensive systematic review for a pragmatic multidisciplinary approach.

Alterio D, Turturici I, **Volpe S***, Ferrari A, Russell-Edu SW, Vischioni B, Mardighian D, Preda L, Gandini S, Marvaso G, Augugliaro M, Durante S, Arculeo S, Patti F, Bocuzzi D, Casbarra A, Starzynska A, Santoni R, Jereczek-Fossa BA.
Crit Rev Oncol Hematol. 2020 Aug 25;155:103088. doi: 10.1016/j.critrevonc.2020.103088. PMID: 32956946.

54. MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).

Gugliandolo SG, Pepa M, Isaksson LJ, Marvaso G, Raimondi S, Botta F, Gandini S, Ciardo D, **Volpe S**, Riva G, Rojas DP, Zerini D, Pricolo P, Alessi S, Petralia G, Summers PE, Mistretta FA, Luzzago S, Cattani F, De Cobelli O, Cassano E, Cremonesi M, Bellomi M, Orecchia R, Jereczek-Fossa BA.

Eur Radiol. 2020 Aug 27. doi: 10.1007/s00330-020-07105-z.

55. Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Alterio D, **Volpe S***, Bacigalupo A, Bonomo P, De Felice F, Dionisi F, D'Onofrio I, D'Angelo E, Di Rito A, Fanetti G, Franco P, Maddalo M, Merlotti A, Micciche F, Orlandi E, Paia F, Ursino S, Pepa M, Corvo R, Di Muzio NG, Magrini SM, Russi E, Sanguineti G, Jereczek-Fossa BA, Donato V, Musio D.

Med Oncol. 2020 Aug 17;37(10):85. doi: 10.1007/s12032-020-01409-2. PMID: 32808089; PMC7430932.

56. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)

Marvaso G, Gugliandolo SG, Bellerba F, Gandini S, Corrao G, **Volpe S**, Rojas DP, Riva G, Zerini D, Pepa M, Fodor CI, La Rocca E, Pricolo P, Alessi S, Petralia G, Mistretta FA, Cambria R, Cattani F, De Cobelli O, Orecchia R, Jereczek-Fossa BA.

Med Oncol. 2020 Jul 28;37(8):74. doi: 10.1007/s12032-020-01397-3. PMID: 32725443.

57. Adjuvant radiotherapy treatment for soft tissue sarcoma of extremities and trunk. A retrospective mono-institutional analysis

Spoto R, Vavassori A, Dicuonzo S, Pepa M, **Volpe S***, Alessandro O, Gandini S, Di Venosa B, Miglietta E, Fodor C, Orsolini G, Prestianni P, Cattani F, Comi S, Lazzari R, Renne G, De Pas T, Orecchia R, Pennacchioli E, Jereczek-Fossa BA

Neoplasma. 2020 Jun, 10.4149/neo_2020_200325N305.

58. Head and neck cancer radiotherapy amid COVID-19 pandemic: Report from Milan, Italy

Alterio D, **Volpe S***, Marvaso G, Turturici I, Ferrari A, Leonardi MC, Lazzari R, Sarra Fiore M, Bufi G, Cattani F, Arrobbio C, Patti F, Casbarra A, Cavallo I, Mastrilli F, Orecchia R, Jereczek-Fossa BA.

Head and Neck. 2020 Jul; 42(7): 1482–1490.

59. Machine learning-based models for prediction of toxicity outcomes in radiotherapy

LJ Isaksson, M Pepa, M Zaffaroni, G Marvaso, D Alterio, **S Volpe**, G Corrao, M Augugliaro, A Starzyńska, MC Leonardi, R Orecchia, BA Jereczek-Fossa

Front. Oncol., 05 June 2020 | <https://doi.org/10.3389/fonc.2020.00790>

60. Dose-volume correlates of the prevalence of patient-reported trismus in long-term survivorship after oropharyngeal IMRT: A cross-sectional dosimetric analysis.

MD Anderson Head and Neck Cancer Symptom Working Group.

Radiother Oncol. 2020 May 6;149:142-149. doi: 10.1016/j.radonc.2020.04.053. PMID: 32387489

61. Impact of a dedicated radiologist as a member of the head and neck tumour board: a single-institution experience.

Alterio D, Preda L, **Volpe S**, Giannitto C, Riva G, Kamga Pounou FA, Atac M, Giugliano G, Bruschini R, Ferrari A, Marvaso G, Cossu Rocca M, Verri E, Rossi D, Bellomi M, Jereczek-Fossa BA, Orecchia R, Ansarin M.

Acta Otorhinolaryngol Ital. 2020 Feb;40(1):26-32. doi: 10.14639/0392-100X-N0326.PMID: 32275646

62. Soft tissue necrosis in patients treated with transoral robotic surgery and postoperative radiotherapy: preliminary results.

Alterio D, Tagliabue M, Muto M, Zorzi S, **Volpe S**, Gandini S, Sibio D, Bayir Ö, Marvaso G, Ferrari A, Bruschini R, Cossu Rocca M, Preda L, Marangoni R, Starzynska A, Vigorito S, Ansarin M, Jereczek-Fossa BA.

Tumori. 2020 Jan 30;300891619900920. doi: 10.1177/0300891619900920 PMID: 31996091

63. Modern radiotherapy for head and neck cancer.

Alterio D, Marvaso G, Ferrari A, **Volpe S**, Orecchia R, Jereczek-Fossa BA.

Semin Oncol. 2019 Jun;46(3):233-245. doi: 10.1053/j.seminoncol.2019.07.002. Epub 2019 Jul 26. PMID: 31378376

64. Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis.

Marvaso G, Ciardo D, Gandini S, Riva G, Frigo E, **Volpe S**, Fodor C, Zerini D, Rojas DP, Comi S, Cambria R, Cattani F, Musi G, De Cobelli O, Orecchia R, Jereczek-Fossa BA.

Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):735-744. doi: 10.1016/j.ijrobp.2019.07.027. Epub 2019 Aug 1.PMID: 31377161

65. Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group.

Orlandi E, Bonomo P, Ferella L, D'Angelo E, Maddalo M, Alterio D, Infante G, Bacigalupo A, Argenone A, Iacovelli NA, Desideri I, Meduri B, Triggiani L, **Volpe S**, Belgioia L, Dionisi F, Romanello DA, Fallai C, Miceli R.
Head Neck. 2019 Oct;41(10):3684-3692. doi: 10.1002/hed.25890. Epub 2019 Jul 29.PMID: 31355972

66. Biomechanical modeling of neck flexion for deformable alignment of the salivary glands in head and neck cancer images.

McCulloch MM, Anderson BM, Cazoulat G, Peterson CB, Mohamed ASR, **Volpe S**, Elhalawani H, Bahig H, Rigaud B, King JB, Ford AC, Fuller CD, Brock KK.
Phys Med Biol. 2019 Sep 5;64(17):175018. doi: 10.1088/1361-6560/ab2f13.PMID: 31269475

67. Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating.

MD Anderson Head Neck Cancer Symptom Working Group.
Radiother Oncol. 2019 Apr;133:35-42. doi: 10.1016/j.radonc.2018.12.023. Epub 2019 Jan 14.PMID: 30935579

68. Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained

S Volpe, BA Jereczek-Fossa, D Zerini, DP Rojas, C Fodor, A Vavassori, P Romanelli, S Vigorito, E Rondi, S Comi, R Cambria, F Cattani, S Dicuonzo, P De Marco, G Beltramo, G Musi, O De Cobelli, G Marvaso, R Orecchia
Neoplasma 2019 Mar 5;66(2):308-314. doi: 10.4149/neo_2018_180723N520. Epub 2018 Nov 25.

69. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer

BA Jereczek-Fossa, A Maucieri, G Marvaso, S Gandini, C Fodor, D Zerini, G Riva, O Alessandro, A Surgo, **S Volpe**, G Fanetti, S Arculeo, MA Zerella, S Parisi, P Maisonneuve, A Vavassori, F Cattani, R Cambria, C Garibaldi, A Starzyńska, G Musi, O De Cobelli, M Ferro, F Nolè, D Ciardo, R Orecchia
Med Oncol . 2018 Nov 27;36(1):9. doi: 10.1007/s12032-018-1233-1.

70. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).

Jereczek-Fossa BA, Rojas DP, Zerini D, Fodor C, Viola A, Fanetti G, **Volpe S**, Luraschi R, Bazani A, Rondi E, Cattani F, Vavassori A, Garibaldi C, Alessi S, Pricolo P, Petralia G, Cozzi G, De Cobelli O, Musi G, Orecchia R, Marvaso G, Ciardo D.
Br J Radiol. 2019 Feb;92(1094):20180494. doi: 10.1259/bjr.20180494. Epub 2018 Nov 9.PMID: 30379566

71. A Prospective Longitudinal assessment of MRI Signal Intensity Kinetics of Non-Target Muscles in Patients with Advanced Stage Oropharyngeal Cancer in Relationship to Radiotherapy Dose and Post-Treatment Radiation-Associated Dysphagia: Preliminary findings from a Randomized Trial.

MD Anderson Quantitative Imaging Working Group.
Radiother Oncol 2018, Aug.

72. Late toxicity of image-guided hypofractionated radiotherapy for prostate: nonrandomized comparison with conventional fractionation.

Jereczek-Fossa BA, Surgo A, Maisonneuve P, Maucieri A, Gerardi MA, Zerini D, Marvaso G, Ciardo D, **Volpe S** et al.
Radiologia Medica 2018, Aug.

73. Nutritional Intervention for Nonsurgical Head and Neck Cancer Patients Treated with Radiation Therapy: Results from a Prospective Stepped-Wedge Clinical Protocol

Volpe S, Marvaso G, Alterio D, Ciardo D, Sabbatini A, Zagallo E, Valoriani F, Fanetti G, Ferrari A, Cossu Rocca M, Ansarin M, Jereczek-Fossa B.A.
Nutrition and Cancer, 2018 Oct;70(7):1051-1059. doi: 10.1080/01635581.2018.1497187. Epub 2018 Oct 1.

74. Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: results of a prospective registry

Kamal M, Mohamed ASR, **Volpe S**, Zaveri J, et al; MD Anderson Head, Neck Cancer Symptom Working Group.
Radiother Oncol. 2018 Jun 28. pii: S0167-8140(18)33310-3. doi: 10.1016/j.radonc.2018.06.013

75. Machine Learning Applications in Head and Neck Radiation Oncology: Lessons from Open-Source Radiomics Challenges

Elhalawani H, Lin TA, **Volpe S**, Mohamed ASR et al, on behalf of MICCAI/M.D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group
Front. Oncol., 17 August 2018 | <https://doi.org/10.3389/fonc.2018.00294>

76. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.

Lazzari R, Ronchi S, Gandini S, Surgo A, **Volpe S***, Piperno G, Comi S, Pansini F, Fodor C, Orecchia R, Tomao F, Parma G, Colombo N, Jereczek-Fossa BA.
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):650-660. doi: 10.1016/j.ijrobp.2018.03.058. Epub 2018 Apr 4.

77. Exploring Applications of Radiomics in Magnetic Resonance Imaging of Head and Neck Cancer: A Systematic Review.

Jethanandani A, Lin TA, **Volpe S**, Elhalawani H, Mohamed ASR, Yang P, Fuller CD.
Front Oncol. 2018 May 14; 8:131. doi: 10.3389/fonc.2018.00131. eCollection 2018.

78. Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.

Timon G, Ciardo D, Bazani A, Marvaso G, Riva G, **Volpe S**, Renne G, Petralia G, Zerini D, Fodor C, Dicuonzo S, Maestri D, Pansini F, Cambria R, Cattani F, Golino F, Scroffi V, De Lorenzo D, De Cobelli O, Orecchia R, Jereczek-Fossa BA.
Br J Radiol. 2018 May 23:20160725. doi: 10.1259/bjr.20160725.

79. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy.

Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, **Volpe S**, Ng SP, Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, Garden AS.
Cancer. 2018 Apr 1;124(7):1415-1427. doi: 10.1002/cncr.31235. Epub 2018 Jan 16.

80. Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.

MD Anderson Head and Neck Cancer Symptom Working Group
Radiother Oncol. 2018 Jan;126(1):75-80. doi: 10.1016/j.radonc.2017.10.037. Epub 2017 Dec 8.

81. Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression.


Alterio D, Marvaso G, Maffini F, Gandini S, Chiocca S, Ferrari A, Preda L, Rocca MC, Lepanto D, Fodor C, **Volpe S**, Dicuonzo S, Laudati A, Giugliano G, Ansarin M, Jereczek-Fossa BA.
Med Oncol. 2017 Oct;34(6):107. doi: 10.1007/s12032-017-0965-7. Epub 2017 Apr 27.

In compliance with the GDPR and the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

Milan, Thursday, August 21, 2025

Yours faithfully,

Stefania Volpe MD, PhD

A handwritten signature in black ink, appearing to read 'Stefania Volpe', written over a horizontal line.

Milano, 20/08/2025

Gentili Colleghi,

Mi chiamo Stefania Volpe, e sono un Medico Specialista in Radioterapia Oncologica presso l'Istituto Europeo di Oncologia IRCCS di Milano, e Ricercatore presso l'Università degli Studi di Milano. Vi scrivo per sottoporvi la mia candidatura come Consigliere del Gruppo di Studio Polmone per il prossimo biennio.

Il mio interesse per la patologia polmonare nasce all'inizio del mio dottorato in System Medicine e Computational Biology, nel corso del quale mi sono concentrata sull'imaging quantitativo nel carcinoma polmonare non a piccole cellule in stadio iniziale.

Da questa esperienza, che mi ha consentito di approfondire aspetti metodologici delle analisi omiche, è derivato lo studio MONDRIAN, che coordino dal 2023 in qualità di Principal Investigator. Il progetto, finanziato da AIRC nell'ambito del grant Next Generation Physician Scientist, mira a integrare dati clinici, radiomici, genomici e proteomici, per lo sviluppo di modelli predittivi di risposta alla SBRT. L'obiettivo è raggiungere una maggiore personalizzazione dei trattamenti radioterapici in questo setting, individuando i migliori candidati a SBRT e prevedendo, in prospettiva, anche l'associazione con terapia sistemica nei casi ad alto rischio.


Da alcuni anni, quindi, il mio interesse clinico e di ricerca si è sempre più orientato verso la patologia polmonare, non limitandosi allo stadio iniziale, ma estendendosi anche alla patologia localmente avanzata e metastatica. In questa fase penso quindi sia importante per me provare a portare la mia esperienza- oltre al desiderio di collaborazione e scambio- in un ambito più ampio, quale quello del Gruppo di Studio AIRO.

Credo sia infatti necessario continuare a costruire un confronto a livello nazionale tra i Radio-Oncologi dedicati alle patologie polmonari, promuovendo la ricerca e la qualità delle cure, e divulgando il ruolo della nostra disciplina tra i diversi professionisti che prendono parte ai gruppi oncologici multidisciplinari.

Se scelta, le mie proposte verterebbero principalmente nell'ambito del tumore polmonare in I e II stadio. Nonostante la SBRT rappresenti una tecnica ampiamente diffusa, infatti, esistono notevoli variazioni in termini di schemi di prescrizione e delivery (quotidiano o a giorni alterni), come ben evidenziato da un recente lavoro di Alfaifi et al. (IJROBP, 2025). Oltre a fornire informazioni sullo stato dell'arte in Italia, un lavoro di questo tipo favorirebbe la generazione condivisa di evidenza e la creazione di un consensus, con l'idea di uniformare quanto possibile i trattamenti sul territorio, definendo un algoritmo di trattamento basato su parametri noti e riproducibili. Inoltre, sono convinta che questo confronto rappresenti la base essenziale per la promozione di futuri studi multicentrici, retrospettivi e soprattutto prospettici nell'ambito della SBRT polmonare. In particolare, penso potrebbe essere interessante valutare gli outcome dei pazienti trattati con diversi frazionamenti e modalità di irradiazione, considerando- e potenzialmente validando- marcatori prognostici facilmente disponibili ma ancora non sostenuti da dati sufficientemente solidi (es: NLR, PLR). Altre possibili proposte potrebbero riguardare lo sviluppo di progetti che comprendano, ad esempio, l'integrazione dell'AI nel workflow della radioterapia per i tumori polmonari, anche in collaborazione con altre società nazionali e/o gruppi di esperti.

Se eletta, mi impegno a mettere a disposizione la mia esperienza clinica e di ricerca per favorire la nascita e lo sviluppo di iniziative condivise, con l'obiettivo di promuovere la collaborazione tra i centri, l'uniformità dei percorsi di cura, e, non ultima, la valorizzazione del contributo della radioterapia polmonare nei team oncologici multidisciplinari.

Con stima,

A handwritten signature in black ink, appearing to read "Stefano Vignoli", written over a horizontal line.